Enhanced oncolytic activity of E4orf6-deficient adenovirus by facilitating nuclear export of HuR.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
20 08 2020
Historique:
received: 14 04 2020
accepted: 29 04 2020
entrez: 25 7 2020
pubmed: 25 7 2020
medline: 13 2 2021
Statut: ppublish

Résumé

An AU-rich element (ARE) is RNA element that enhances the rapid decay of mRNA. The RNA binding protein HuR stabilizes ARE-mRNA by exporting it to the cytoplasm. In most of cancer cells, HuR is exported to the cytoplasm and ARE-mRNA is stabilized. In addition, the viral gene product E4orf6 exports HuR to stabilize ARE-mRNA in adenovirus-infected cells and the stabilization is required for full virus replication. Previously we showed the oncolytic activity of E4orf6-deleted adenovirus dl355, which can replicate in cancer cells where ARE-mRNA is stabilized. In this study, we examined whether the further enhancement of HuR export can stimulate the replication and the oncolytic activity of dl355. We found that ethanol treatment promoted the cytoplasmic relocalization of HuR in cancer cells. In addition, the replication efficiency of dl355 increased in ethanol-treated cells, and in response, the cytolytic activity of the virus also increased in vitro and in vivo. Upregulation of a cleaved-PARP level in infected cells mediated by ethanol is suggesting that ethanol activated the apoptosis induced by dl355. IVa2 mRNA, the only ARE-mRNA among transcripts of adenovirus was augmented by ethanol treatment. These data indicate that the enhancement of ARE-mRNA stabilization as a result of ethanol treatment upregulates the oncolytic activity of dl355 and suggests that the combined use of an oncolytic adenovirus and ethanol treatment may be a good strategy for cancer therapy.

Identifiants

pubmed: 32703457
pii: S0006-291X(20)30887-1
doi: 10.1016/j.bbrc.2020.04.147
pii:
doi:

Substances chimiques

Adenovirus E4 Proteins 0
E4orf6 protein, adenovirus 0
ELAV-Like Protein 1 0
ELAVL1 protein, human 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-499

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declared that there is no conflicts of interest.

Auteurs

Ishraque Ahmed (I)

Department of Molecular Oncology, Hokkaido University Faculty of Dental Medicine and Graduate School of Biomedical Science and Engineering, Sapporo, Japan.

Mohammad Towfik Alam (MT)

Department of Vascular Biology and Molecular Pathology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan; Department of Dental Radiology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan.

Aya Yanagawa-Matsuda (A)

Department of Vascular Biology and Molecular Pathology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan.

Elora Hossain (E)

Department of Molecular Oncology, Hokkaido University Faculty of Dental Medicine and Graduate School of Biomedical Science and Engineering, Sapporo, Japan.

Tetsuya Kitamura (T)

Department of Vascular Biology and Molecular Pathology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan.

Kazuyuki Minowa (K)

Department of Dental Radiology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan.

Fumihiro Higashino (F)

Department of Molecular Oncology, Hokkaido University Faculty of Dental Medicine and Graduate School of Biomedical Science and Engineering, Sapporo, Japan; Department of Vascular Biology and Molecular Pathology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan. Electronic address: fhigashi@den.hokudai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH